AstraZeneca and Johnson & Johnson have restarted their late-stage trials after finding that serious illnesses in a few volunteers appeared not to be related to the vaccines.
In a highly anticipated meeting of the agency’s vaccine advisory board, some said that the current guidelines, which require two months of safety data after a volunteer has been vaccinated, were not enough.
The move indicated that the drug had cleared more rigorous hurdles since it was given emergency authorization in May.
In 2016, agency scientists deemed hair straighteners containing formaldehyde to be unsafe, according to newly obtained emails.
All the weak points of American health care — testing delays, communication breakdowns, inequity — are working against this potential treatment.
Friday’s announcement represents a shift in tone for the company and its leader, who has repeatedly emphasized the month of October in interviews and public appearances.
The two-drug combination invented by college students is one of many potential therapies being tested for this paralyzing fatal condition.
Downplaying the dangers of the pandemic and politicizing public health measures was grossly negligent and cost untold lives.
In a small study in San Francisco, Abbott’s BinaxNOW identified infectious people nearly as accurately as a P.C.R. test.
As America retreats from world affairs, Russia is promising other nations help on the pandemic.
A network of scientists is chasing the pandemic’s holy grail: an antibody that protects against not just the virus, but also related pathogens that may threaten humans.
Come spring, Americans may have their choice of several so-so coronavirus vaccines — with no way of knowing which one is best.
The reversal came just hours after the federal government threatened the state, calling the prohibition on the tests “illegal.”
The agency prides itself on avoiding Washington partisanship. But the White House has successfully pushed the agency to revise guidelines on matters like school reopenings and church gatherings.
Emergency-use authorizations, a formerly obscure corner of regulatory law, have become a centerpiece of the government’s response to the pandemic.
A federal judge, citing the pandemic, had suspended a federal requirement that women seeking medication abortions pick up a pill in person.
Two tests made by Quidel and BD repeatedly delivered false-positive results, prompting the state to stop using them.
The F.D.A. releases guidelines that had been trailed by politics: This is your morning tip sheet.
The F.D.A. proposed stricter guidelines for emergency approval of a coronavirus vaccine, but the White House chief of staff objected to provisions that would push approval past Election Day.
Speed and scale may matter more than absolute effectiveness when it comes to tests, masks, treatments and vaccines.
In what could be the first step in the development of a significant new line of business for the telemedicine prescription provider Ro, the company is finally announcing the general commercial availability of weight loss product, Plenity.
Developed by Gelesis, a biotech company that makes treatments for gastro-intestinal disorders, Plentiy is a weight loss treatment that uses citric acid and cellulose to create a non-toxic paste that makes people feel more full after they ingest it. Taken before meals, the pill becomes a substance that expands to take up about 25% of the stomach, so people eat less.
The product has been approved by the U.S. Food and Drug Administration and is available for a much broader segment of the population than other weight loss products. While most prescription medicines are intended for people who are obese, the Gelesis product is made for people who are overweight, too.
“That’s adults who have a BMI from 25 up to 40. That’s 150 million Americans,” according to Gelesis chief commercial and operating officer, David Pass.
Plenity received FDA approval last April and Gelesis started working with Ro soon after, according to Pass. The idea was to craft a strategy that could get the treatment, which is classified as a medical device and not a drug, in the hands of as many patients as quickly as possible.
For Ro, the agreement with Gelesis is a sign of potential things to come. The company is the exclusive online provider of the Plenity treatment and Ro founder Zachariah Reitano said that there’s an incredible potential to engage in more of these types of deals.
“We would love to be able to partner with pharmaceutical companies to decrease the cost of distribution,” said Reitano. “We were excited to build an exciting treatment solution for weight management. Our high-level mission is to be the patient’s first call.”
With the Gelesis partnership Ro can add another highly desirable treatment to its roster of therapies — and one that can be a contributing factor to increasing the severity of other conditions that the company already provides treatment for, Reitano said.
“There are a few conditions that we currently treat that are exacerbated by a patient being overweight or obese. People who struggle with weight management will also experience ED. Obesity can lead to heart failure stroke, coronary heart disease, hypetension, depression,” Reitano said. “The breadth of the label is interesting. Only FDA approved with a BMI from 25 to 40. FDA approved treatment have been between 30 and 40. [It] makes the treatment more accessible to a wider variety of people.”
As the only online provider of the treatment, Ro has developed an onboarding process to ensure that the Plenity therapy isn’t abused by people who suffer from eating disorders.
“During our onboarding we not only ask questions to patients about their weight management. There’s a consecutive set of images that need to be uploaded and taken with the provider. That’s something we’ve taken a lot of time and energy to make sure about,” said Reitano.
Like the other treatments Ro offers, Plenity is a cash pay prescription, because the weight loss treatments aren’t typically covered by insurance, he said.
The benefit of working with an online pharmacy like Ro to provide distribution for a new therapy was obvious to both startups.
“We turned this market on its head by putting the consumer at the heart of everything we do,” said Pass. The treatment costs $98 per month, compared to other therapies or branded medications that could be as much $300 and $350 per month, according to Pass.
One reason that Gelesis is able to reduce the price of the drug is that it won’t have to hire a massive sales force to pitch it. The company has Ro for that.
“Normally you have a pharmaceutical company that would have to hire a sales force and go door to door and it increases the cost of a new drug. [Ro] can make a new, innovative treatment available, like Plenity, available nationwide,” Reitano said.
Despite slim chances that its vaccine will be ready by October, Pfizer has big incentives to hint that it might be.
Bully and ignore the experts, and send in the quacks.
New York officials do not play a role in the approval of a vaccine, but could delay distribution if they believed the vaccine was not safe.
Benzodiazepines — commonly prescribed for anxiety, insomnia, seizures and panic disorders — are highly addictive and come with health risks, especially when combined with other drugs.
The new guidelines underscore the fact that a vaccine is highly unlikely before the election.
Experts said the memo would make it more difficult for the F.D.A. to issue new rules, but it’s unclear how it would affect the vetting of coronavirus vaccines.
Despite the president’s repeated claims that a vaccine will be available in October, scientists, companies and federal officials all say that most people won’t get one until well into next year.
Researchers say drug companies need to be more open about how vaccine trials are run to reassure Americans who are skittish about getting a coronavirus vaccine.
New details of how the president has demanded faster action from health agencies help explain the intensifying concern that he could demand pre-Election Day approval of a vaccine.
It’s simple. Everything that benefits Mr. Trump is true and everything that inconveniences him is false.
A group of career scientists at the Food and Drug Administration vowed that their work would continue unimpeded and independent of political influence.
The president is the Coronavirus vaccine’s worst hype man.
The statement is meant to reassure the public that the companies will not seek a premature approval of vaccines under pressure from the Trump administration.
A study of their therapy and clinical trials of other experimental treatments are offering glimmers of hope that paralysis from the disorder can be slowed.
Six months into the pandemic and with no coherent national testing strategy, the Trump administration is encouraging private development of an array of faster and cheaper techniques.
More than 70,000 Covid-19 patients have received it. We have no idea whether it helps.
Here’s how: Follow Britain’s example.
The usual diagnostic tests may simply be too sensitive and too slow to contain the spread of the virus.
The agency’s chief spokeswoman, Emily Miller, was removed from her position just 11 days into the job. And the contract was terminated of a consultant who had advised the F.D.A. chief to correct misleading claims about plasma’s benefits.
Our readers sent in smart questions about this thorny issue.
Stephen Hahn made misleading remarks about a coronavirus treatment. How did that happen?
As summer draws to a close, four new developments in the treatment and understanding of the coronavirus have arisen in the United States and abroad.
Sowing doubt about the safety of treatments will imperil the fight against coronavirus in the months and years to come.